Original Article

You have full text access to this OnlineOpen article

Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: A decision analysis

  1. A. Mark Fendrick1,
  2. Rajesh R. Bandekar2,
  3. Michael E. Chernew1,
  4. James M. Scheiman1,*

Article first published online: 7 FEB 2002

DOI: 10.1002/art1.10159

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 47, Issue 1, pages 36–43, February 2002

Additional Information

How to Cite

Fendrick, A. M., Bandekar, R. R., Chernew, M. E. and Scheiman, J. M. (2002), Role of initial NSAID choice and patient risk factors in the prevention of NSAID gastropathy: A decision analysis. Arthritis & Rheumatism, 47: 36–43. doi: 10.1002/art1.10159

Author Information

  1. 1

    Consortium for Health Outcomes, Innovation, and Cost-Effectiveness Studies (CHOICES), Univer-sity of Michigan School of Medicine, Ann Arbor, Michigan

  2. 2

    Consortium for Health Outcomes, Innovation, and Cost-Effectiveness Studies (CHOICES), University of Michigan School of Medicine

*University of Michigan Medical Center, 2912 Taubman Center Box 0362, Ann Arbor, MI 48109-0362

Publication History

  1. Issue published online: 7 FEB 2002
  2. Article first published online: 7 FEB 2002
  3. Manuscript Accepted: 1 JUL 2001
  4. Manuscript Received: 5 APR 2001

Funded by

  • SmithKline Beecham

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (138K)

REFERENCES

  • 1
    Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of NSAIDS: a meta-analysis Ann Intern Med 1991; 115: 787–96.
  • 2
    Wolfe MM, Lichtenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs N Engl J Med 1999; 340: 1888–99.
  • 3
    Smalley WE, Griffin MR, Fought RL, Ray WA. Excess costs from gastrointestinal disease associated with nonsteroidal anti-inflammatory drugs J Gen Intern Med 1996; 11: 461–9.
  • 4
    Paulus HE. FDA Arthritis Advisory Committee meeting: postmarketing surveillance of nonsteroidal antiinflammatory drugs Arthritis Rheum 1985; 28: 1168–9.
    Direct Link:
  • 5
    Goldstein JL. Public misunderstanding of nonsteroidal antiinflammatory drug (NSAID)-mediated gastrointestinal complications toxicity: a serious potential health threat Gastroenterology 1998; 114: G0555.
  • 6
    Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial Fam Med 1996; 28: 204–10.
  • 7
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The class study: a randomized controlled trial JAMA 2000; 284: 1247–55.
  • 8
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis N Engl J Med 2000; 343: 1505–84.
  • 9
    De Pouvourville G. Preventing NSAID-induced gastrointestinal toxicity. Economic considerations, methodological problems and results Pharmacoeconomics 1995; 7: 99–110.
  • 10
    Knill-Jones R, Drummond M, Kohli H, Davies L. Economics evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs Postgrad Med J 1990; 66: 639–46.
  • 11
    Al MJ, Bowine MC, Rutten FH. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis Pharmacoeconomics 1996; 10: 141–51.
  • 12
    Maetzel A, Ferraz MB, Bombardier C. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs Arthritis Rheum 1998; 41: 16–25.
    Direct Link:
  • 13
    Walt RP. Misoprostol for the treatment of peptic ulcer and antiinflammatory drug induced gastroduodenal ulceration N Engl J Med 1992; 327: 1575–80.
  • 14
    Johnson RE, Hornbrook MC, Hooker RS, Woodson GT, Shneidman R. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organization Pharmacoeconomics 1997; 12: 76–88.
  • 15
    Graham, DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand Am J Gastroenterol 1996; 91: 2080–6.
  • 16
    Bijilsma J, Multicenter Group. Treatment of endoscopy negative NSAID-induced upper gastrointestinal symptoms with cimetidine: an international multicenter collaborative study Aliment Pharmacol Ther 1988; 2S: 75.
  • 17
    Koch M, Dezi A, Ferrario F, Capso L. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials Arch Intern Med 1996; 156: 2321–32.
  • 18
    Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Tryne PN, Cottrell J, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal anti-inflammatory drugs N Engl J Med 1996; 334: 1435–9.
  • 19
    Hawkey CJ, Karrasch JA, Szczepanski L, Walker DG, Barkun A, Susannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs N Engl J Med 1998; 338: 727–34.
  • 20
    Cullen D, Bardhan KD, Eisner M, Kogut DG, Peacock RA, Thomson JM, et al. Primary gastroduodenal prophylaxis with omeprazole for NSAID users Aliment Pharmacol Ther 1998; 12: 135–40.
    Direct Link:
  • 21
    Ekstrom P, Carling L, Wetterhus S, Wingren PE, anker-Hansen O, Lundegardh G, et al. Omeprazole reduces the frequency of gastroduodenal lesions and dyspeptic symptoms during NSAID treatment Scand J Gastroenterol 1996; 31: 753–8.
  • 22
    Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, et al. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation Proc Natl Acad Sci U S A 1994; 91: 2046–50.
  • 23
    Scheiman, JM. NSAIDs, cytoprotection, and gastrointestinal injury Gastroenterol Clin North Am 1996; 25: 279–98.
  • 24
    Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide Med Decis Making 1993; 13: 322–38.
  • 25
    Armstrong CP, Blower AI. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration Gut 1987; 28: 527–32.
  • 26
    Larkai EN, Smith JL, Lidsky MD, Sessoms SL, Graham DY. Dyspepsia in NSAID users: the size of the problem J Clin Gastroenterol 1989; 11: 158–62.
  • 27
    Fendrick AM, Scheiman, JM. Decision analytic modeling and NSAID gastropathy: could we be more sensitive? J Gen Intern Med 2000; 15: 430–1.
    Direct Link:
  • 28
    Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998; 338: 719–26.
  • 29
    Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicenter, double-blind, placebo-controlled trial. Lancet 1988; ii: 1277–80.
  • 30
    Walan A, Bader JP, Classen M, Lamers CB, Piper DW, Rutgersson K, et al. Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N Engl J Med 1989; 320: 69–75.
  • 31
    Raskin JB, White RH, Jackson JE. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344–50.
  • 32
    Raskin JB, White R, Jaszewski R, Korsten MA, Schubert TT, Fort JG. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double blind, multicenter study. Am J Gastroenterol 1996; 91: 223–7.
  • 33
    Ehsanullah RS, Page MC, Tildesley G, Wood JR. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988; 297: 1017–21.
  • 34
    Robinson MG, Griffin JW Jr, Bowers J, Kogan FJ, Kogut DG, Lanza FI, et al. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci 1989; 34: 424–8.
  • 35
    Levine LR, Cloud ML, Enas NH. Nizatidine prevents peptic ulceration in high-risk patients taking nonsteroidal anti-inflammatory drugs. Arch Intern Med 1993; 153: 2449–54.
  • 36
    Silverstein FE, Graham DY, Senior JR, Davies HW, Struthers B, Bittman RM, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized double-blind, placebo controlled trial. Ann Intern Med 1995; 123: 241–9.
  • 37
    Roth SH, Tindall EA, Jain AK, McMahon FG, April PA, Bockow BI, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal mucosa. Arch Intern Med 1993; 153: 2565–71.
  • 38
    Lipani JA, Poland M. Clinical update of the relative safety of nabumetone in long-term clinical trials. Inflammopharmacology 1995; 3: 351–61.
  • 39
    Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134–43.
  • 40
    Laine L, Hawkey CJ, Bombardier C, Shapiro D, Reicin A. Stratifying the risk of clinical upper GI events in NSAID users: results from a double-blind outcomes study [abstract]. Gastroenterology 2001; 120: A105.
  • 41
    Peterson WL, Cryer B. COX-1 sparing NSAIDs: is the enthusiasm justified? JAMA 2000; 282: 1961–3.
View Full Article (HTML) Get PDF (138K)